S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
Log in
NYSE:BHVN

Biohaven Pharmaceutical News Headlines

$63.51
+0.66 (+1.05 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$62.32
Now: $63.51
$64.38
50-Day Range
$59.04
MA: $62.53
$67.65
52-Week Range
$26.56
Now: $63.51
$78.75
Volume773,560 shs
Average Volume837,179 shs
Market Capitalization$3.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22

Headlines

Biohaven Pharmaceutical (NYSE BHVN) News Headlines Today

Source:
DateHeadline
Biohaven Pharmaceutical (NYSE:BHVN) Given New $57.00 Price Target at Morgan StanleyBiohaven Pharmaceutical (NYSE:BHVN) Given New $57.00 Price Target at Morgan Stanley
marketbeat.com - August 24 at 8:09 AM
William Blair Reiterates "Buy" Rating for Biohaven Pharmaceutical (NYSE:BHVN)William Blair Reiterates "Buy" Rating for Biohaven Pharmaceutical (NYSE:BHVN)
marketbeat.com - August 10 at 9:13 AM
Biohaven Pharmaceutical (NYSE:BHVN) Shares Up 4% Following Analyst UpgradeBiohaven Pharmaceutical (NYSE:BHVN) Shares Up 4% Following Analyst Upgrade
marketbeat.com - June 18 at 2:33 PM
New Haven-based Biohaven Pharmaceuticals advances additional migraine drugsNew Haven-based Biohaven Pharmaceuticals advances additional migraine drugs
msn.com - September 17 at 6:55 PM
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director John W. Childs Purchases 6,678 SharesBiohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director John W. Childs Purchases 6,678 Shares
americanbankingnews.com - September 14 at 9:32 PM
Biohavens Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human DosingBiohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
prnewswire.com - September 10 at 10:30 AM
Biohaven launches early-stage study of oral migraine med zavegepantBiohaven launches early-stage study of oral migraine med zavegepant
seekingalpha.com - September 10 at 10:30 AM
Biohaven Pharma Advances Oral Formulations Of Zavegepant Into Human StudiesBiohaven Pharma Advances Oral Formulations Of Zavegepant Into Human Studies
nasdaq.com - September 10 at 10:30 AM
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human DosingBiohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
finance.yahoo.com - September 10 at 10:30 AM
-$2.80 Earnings Per Share Expected for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) This Quarter-$2.80 Earnings Per Share Expected for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) This Quarter
americanbankingnews.com - September 9 at 12:06 AM
Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple MyelomaKleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma
finance.yahoo.com - September 8 at 1:57 PM
Hedge Funds Have Been This Bullish On Biohaven Pharmaceutical (BHVN)Hedge Funds Have Been This Bullish On Biohaven Pharmaceutical (BHVN)
finance.yahoo.com - September 2 at 3:11 PM
Biohaven Pharmaceutical (NYSE:BHVN) Shares Up 5.2%Biohaven Pharmaceutical (NYSE:BHVN) Shares Up 5.2%
americanbankingnews.com - August 31 at 7:17 PM
Biohaven, Casava, Shoinigi Taking Different Approaches to AlzheimersBiohaven, Casava, Shoinigi Taking Different Approaches to Alzheimer's
finance.yahoo.com - August 27 at 2:44 PM
Biohaven Is Still A Bargain On Increasing Nurtec ODT SalesBiohaven Is Still A Bargain On Increasing Nurtec ODT Sales
seekingalpha.com - August 26 at 8:41 AM
Morgan Stanley Lowers Biohaven Pharmaceutical (NYSE:BHVN) Price Target to $57.00Morgan Stanley Lowers Biohaven Pharmaceutical (NYSE:BHVN) Price Target to $57.00
americanbankingnews.com - August 24 at 8:09 AM
Noteworthy Wednesday Option Activity: APO, BHVN, CRMNoteworthy Wednesday Option Activity: APO, BHVN, CRM
nasdaq.com - August 12 at 6:53 PM
Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec UptakeBiohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake
finance.yahoo.com - August 10 at 1:40 PM
Biohaven Pharmaceuticals Q2 2020 Earnings PreviewBiohaven Pharmaceuticals Q2 2020 Earnings Preview
seekingalpha.com - August 9 at 2:12 PM
Biohaven secures funding deal with Royalty Pharma valued up to $450MBiohaven secures funding deal with Royalty Pharma valued up to $450M
seekingalpha.com - August 7 at 1:53 PM
Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020
finance.yahoo.com - August 5 at 9:32 PM
Biohaven initiates late-stage study with verdiperstat in a rare neuromuscular disorderBiohaven initiates late-stage study with verdiperstat in a rare neuromuscular disorder
seekingalpha.com - August 3 at 5:13 PM
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General HospitalBiohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital
finance.yahoo.com - August 3 at 12:12 PM
Biohavens Phase 3 Trial, And Other News: The Good, Bad And Ugly Of BiopharmaBiohaven's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - July 22 at 8:07 PM
Biohaven completes enrollment in late-stage verdiperstat study in rare neurological disorderBiohaven completes enrollment in late-stage verdiperstat study in rare neurological disorder
seekingalpha.com - July 21 at 1:17 PM
Taking a Wait and Watch Strategy on Biohaven PharmaceuticalTaking a Wait and Watch Strategy on Biohaven Pharmaceutical
finance.yahoo.com - July 16 at 8:28 AM
Biohaven and Khloe Kardashian Team Up to Promote Migraine DrugBiohaven and Khloe Kardashian Team Up to Promote Migraine Drug
www.thestreet.com - July 15 at 7:13 PM
Khloe Kardashian Adds Biohaven Migraine Drug to Brand ToutsKhloe Kardashian Adds Biohaven Migraine Drug to Brand Touts
finance.yahoo.com - July 15 at 2:12 PM
Biohaven and Khloe Kardashian Team to Promote Migraine DrugBiohaven and Khloe Kardashian Team to Promote Migraine Drug
finance.yahoo.com - July 15 at 2:12 PM
After Living with Migraine for Years, Khloé Kardashian Leads Biohavens Take Back Today Campaign to Empower People with MigraineAfter Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine
www.prnewswire.com - July 15 at 9:12 AM
After Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with MigraineAfter Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine
finance.yahoo.com - July 15 at 9:12 AM
Did Hedge Funds Make The Right Call On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)Did Hedge Funds Make The Right Call On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
finance.yahoo.com - July 13 at 2:50 PM
Did Hedge Funds Make The Right Call On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ?Did Hedge Funds Make The Right Call On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ?
finance.yahoo.com - July 13 at 2:50 PM
Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected PatientsKleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients
finance.yahoo.com - July 8 at 9:13 AM
Biohavens troriluzole flunks obsessive-compulsive disorder studyBiohaven's troriluzole flunks obsessive-compulsive disorder study
seekingalpha.com - June 24 at 8:21 AM
Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program UpdateBiohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update
finance.yahoo.com - June 24 at 8:21 AM
Noteworthy Thursday Option Activity: GS, BHVN, ALLKNoteworthy Thursday Option Activity: GS, BHVN, ALLK
www.nasdaq.com - June 18 at 6:44 PM
Biohaven Presents NURTEC™ (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific MeetingBiohaven Presents NURTEC™ (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
finance.yahoo.com - June 16 at 8:45 AM
Biohaven Appoints Bob Hugin to its Board of DirectorsBiohaven Appoints Bob Hugin to its Board of Directors
finance.yahoo.com - June 10 at 8:44 AM
Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) A Good Stock To Buy?Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) A Good Stock To Buy?
finance.yahoo.com - June 6 at 6:23 PM
Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare ConferenceKleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference
finance.yahoo.com - June 1 at 8:01 PM
Biohaven Pharmaceutical Holding Co. Ltd.Biohaven Pharmaceutical Holding Co. Ltd.
www.marketwatch.com - May 25 at 12:34 AM
Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple MyelomaKleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma
finance.yahoo.com - May 21 at 8:33 AM
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual PlatformBiohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
finance.yahoo.com - May 18 at 10:21 AM
Biohaven Pharmaceutical Offers Good Value With Nurtec ODT Now On The MarketBiohaven Pharmaceutical Offers Good Value With Nurtec ODT Now On The Market
seekingalpha.com - May 16 at 5:45 PM
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual MeetingKleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting
finance.yahoo.com - May 15 at 8:10 AM
Biohaven Pharmaceutical EPS beats by $0.07, beats on revenueBiohaven Pharmaceutical EPS beats by $0.07, beats on revenue
seekingalpha.com - May 8 at 3:02 AM
Biohaven Pharmaceuticals EPS beats by $0.07, beats on revenueBiohaven Pharmaceuticals EPS beats by $0.07, beats on revenue
seekingalpha.com - May 7 at 10:00 PM
Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business DevelopmentsBiohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
finance.yahoo.com - May 7 at 5:00 PM
Why Biohaven (BHVN) Might Surprise This Earnings SeasonWhy Biohaven (BHVN) Might Surprise This Earnings Season
finance.yahoo.com - May 4 at 4:05 PM
Biohaven up 5% on rimegepant distribution deal in Middle EastBiohaven up 5% on rimegepant distribution deal in Middle East
seekingalpha.com - April 27 at 12:16 PM
Biohaven Pharmaceutical Holding Co LtdBiohaven Pharmaceutical Holding Co Ltd
www.bloomberg.com - April 25 at 10:24 PM
Notable Thursday Option Activity: BHVN, GS, DISNotable Thursday Option Activity: BHVN, GS, DIS
www.nasdaq.com - April 16 at 8:58 PM
This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.